SARS-CoV-2 spike antibodies cross-react with dengue virus and enhance infection in vitro and in vivo

  1. Kamini Jakhar
  2. Sudipta Sonar
  3. Gagandeep Singh
  4. Tejeswara Rao Asuru
  5. Garima Joshi
  6. Nisha Beniwal
  7. Tania Sarkar
  8. Mahima Tiwari
  9. Jaskaran Kaur
  10. Deepak Kumar Rathore
  11. Banwari Lal
  12. Sandeep Kumar
  13. Puneet Srivastav
  14. Satendra Kumar
  15. Vikas Phagna
  16. Sushma Mithina
  17. Lokesh Kumar
  18. Vishal Gupta
  19. Pallavi Kshetrapal
  20. Savita Singh
  21. Nitya Wadhwa
  22. Ramachandran Thiruvengadam
  23. Sreevatsan Raghavan
  24. Mudita Gosain
  25. Tripti Shrivastava
  26. Sankar Bhattacharyya
  27. Shailendra Asthana
  28. Prasenjit Guchhait
  29. Shailendra Mani
4 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

The presence of non-neutralizing antibodies of any dengue serotype, increase the severity of subsequent infection by other dengue serotypes. During SARS-CoV-2 pandemic, the number of symptomatic dengue cases increased in India. We describe that antibodies isolated from convalescent plasma from COVID-19 patients enhances DENV2 infection in vitro. CR3022, one antibody against SARS-CoV-2 spike protein, also showed elevated DENV2 infection in vitro. In silico protein-protein interactions between the spike antibodies and the DENV2 E-protein revealed significant interactions. Likewise, few monoclonal/polyclonal antibodies against SARS-CoV-2 showed increased dengue infection in vitro. Importantly, the AG129 mice infected with SARS-CoV-2 three-weeks prior to DENV2 infection, showed elevated dengue pathogenesis. Thus, highlighting the possibilities of elevated infection and symptomatic dengue disease in COVID-19 survivors.

Related articles

Related articles are currently not available for this article.